摘要
目的 观察紫杉醇（TAX）联合卡铂（CBP）治疗老年人ⅢB～Ⅳ期非小细胞肺癌（NSCLC）的临床疗效和不良反应.方法 将79例经病理检查确诊为非小细胞肺癌的患者按年龄分为3个组：A组年龄＞70岁;B组,60岁≤年龄＜70岁;C组,年龄＜60岁.采用TC方案治疗,TAX 135 mg/m^2,d1,CBP AUC=5～6,d1.每21～28天为1个周期.结果 3组的有效率、1年生存率、临床获益率和肿瘤进展时间分别为31.5%、35.2%、78.1%和5.2个月;32.4%、36.4%、81.2%和6.1个月;32.8%、35.6%、79.8%和5.7个月,3组无显著性差异.3组患者治疗后的血液、肝肾功能、消化道不良反应均无显著性差异.结论 TC方案治疗老年晚期NSCLC有一定疗效,不良反应患者能耐受.
Objective To assess the efficacy and safety of the combination of paditaxel and carboplatin in elderly patients with advanced non-small cell lung cancer（NSCLC）. Methods The patients were divided into three groups by aged ：group A≥70, group B 60≤age〈70 and group C〈60. Paclitaxel 135 mg/m^2 were given intravenously one day1 ,combined with cahoplatin AUC = 5--6 one day1 ,with 21--28 days as a cycle. Results The RR ,one-year survival, CCR and TTP in group A,B and C were 31.5%, 35.2 % ,78.1% and 5.2months; 32.4 %, 36.4 %, 81.2 % and 6.1months; 32.8 %, 35.6 %, 79.8 and 5.7months, respectively. There were no significant differences among three groups. Hematological, renal, hepatic, gastro-intestinal toxicities were similar in three groups. Conclusion The regimens of TC for elderly patients with advanced NSCLC is effective and well-tolerable.
出处
《实用癌症杂志》
2006年第4期379-380,共2页
The Practical Journal of Cancer
关键词
非小细胞肺癌
老年人
化学治疗
紫杉醇
卡铂
Non-small-cell lung cancer（NSCLC）
Elderly patients
Chemotherapy
Paclitaxel
Caboolatin
